Breast cancer drug combo safety study ends early with only 4 patients
NCT ID NCT04967248
First seen Jan 04, 2026 · Last updated May 15, 2026 · Updated 17 times
Summary
This study aimed to track side effects, especially high blood sugar, in people with a certain type of advanced breast cancer taking alpelisib plus fulvestrant. It was designed to observe real-world use, not test if the treatment works. Only 4 people enrolled before the study was stopped early.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HORMONE RECEPTOR POSITIVE HER2 NEGATIVE BREAST CANCER WITH A PIK3CA MUTATION are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.